Subject(s)
Cholestasis/surgery , Common Bile Duct/surgery , Gastrectomy , Gastroenterostomy/methods , Hepatic Duct, Common/surgery , Magnets , Suture Techniques/instrumentation , Aged , Anastomosis, Surgical/instrumentation , Cholangiopancreatography, Magnetic Resonance , Cholestasis/complications , Cholestasis/diagnosis , Female , Humans , Pyloric Stenosis/complications , Pyloric Stenosis/surgery , Tomography, X-Ray ComputedABSTRACT
Severe bleeding following endoscopic biliary sphincterotomy (EBS) can sometimes be difficult to manage, resulting in the need for an invasive intervention. The aim of this study was to retrospectively evaluate the feasibility and efficacy of endoscopic hemostasis using covered self-expandable metallic stents (SEMSs) for severe post- EBS bleeding. Eleven patients with bile duct stones underwent standard EBS using a standard sphincterotome-based technique at 4 endoscopic units of a university-affiliated hospital and a general hospital. Monotherapy or combined therapy were used to achieve hemostasis with either balloon tamponade, hypertonic saline epinephrine injection, or endoclip placement. When active bleeding could not be controlled, covered SEMSs were placed across the major papilla. Emergency endoscopy was performed on the day of admission or the subsequent day (ranging from 6 to 35 h after admission). Bleeding was classified as mild in 6 cases (54.5 %) and moderate in 5 (45.5 %). A covered SEMS 10mm in diameter and 6 cm long was placed across the papilla. After placement, complete hemostasis was achieved. The mean duration of stent placement was 8.2 days (range 510 days), and the SEMS was successfully removed in all cases. Although the present study has the limitations of a small sample size and lack of control patients, covered SEMS placement for endoscopic hemostasis may be useful in selected patients with uncontrolled post-EBS bleeding.
Subject(s)
Hemorrhage/therapy , Hemostasis, Endoscopic , Sphincterotomy, Endoscopic/adverse effects , Stents , Aged , Aged, 80 and over , Coated Materials, Biocompatible , Emergencies , Female , Hemorrhage/diagnosis , Hemorrhage/etiology , Humans , Male , Middle AgedABSTRACT
AIMS: The pepsinogen (PG) test result is used in Japan for screening for gastric cancer. In this study, we investigated the changes in evaluation of the PG test result following H. pylori eradication. METHODS: The subjects were 120 consecutive H. pylori-positive patients with upper gastrointestinal symptoms. Subjects underwent endoscopy prior to, and at 2 months after the eradication therapy, at which time blood was taken for determination of changes in PG levels. RESULTS: The overall eradication rate was 79.3% (per protocol). Following eradication therapy, the evaluation of PG test result converted from positive to negative in 80.4% (37/46) of cases of successful eradication, and in 0% (0/6) of cases of eradication failure. CONCLUSIONS: These results suggest that the evaluation of PG test result should be used after the definitive confirmation of the success or failure of H. pylori eradication therapy.
Subject(s)
Gastrointestinal Diseases/drug therapy , Helicobacter Infections/drug therapy , Helicobacter pylori , Pepsinogens/blood , Anti-Bacterial Agents/therapeutic use , Anti-Ulcer Agents/therapeutic use , Female , Gastric Mucosa/microbiology , Gastrointestinal Diseases/microbiology , Humans , Male , Prospective Studies , Sensitivity and Specificity , Treatment OutcomeSubject(s)
Autoimmune Diseases/diagnosis , Cholangiopancreatography, Endoscopic Retrograde , Cholestasis, Extrahepatic/diagnosis , Common Bile Duct Diseases/diagnosis , Granuloma, Plasma Cell/diagnosis , Pancreatitis/diagnosis , Aged , Autoimmune Diseases/pathology , Biopsy , Cholestasis, Extrahepatic/pathology , Common Bile Duct/pathology , Common Bile Duct Diseases/pathology , Diagnosis, Differential , Granuloma, Plasma Cell/pathology , Humans , Male , Pancreatitis/pathologySubject(s)
Adhesives/therapeutic use , Cyanoacrylates/therapeutic use , Duodenal Diseases/surgery , Duodenoscopy , Intestinal Fistula/surgery , Pancreatic Fistula/surgery , Aged , Cholangiopancreatography, Endoscopic Retrograde , Duodenal Diseases/diagnosis , Female , Humans , Intestinal Fistula/diagnosis , Pancreatic Fistula/diagnosisSubject(s)
Bile Duct Neoplasms/surgery , Bile Ducts, Intrahepatic , Cholangiocarcinoma/surgery , Cholangiopancreatography, Endoscopic Retrograde/methods , Stents , Aged , Bile Duct Neoplasms/diagnosis , Cholangiocarcinoma/diagnosis , Drainage/instrumentation , Drainage/methods , Female , Follow-Up Studies , Humans , Jaundice, Obstructive/diagnosis , Jaundice, Obstructive/etiology , Magnetics , Minimally Invasive Surgical Procedures/methods , Risk Assessment , Treatment OutcomeABSTRACT
BACKGROUND AND STUDY AIMS: The aim of this prospective study was to compare endoscopic ultrasonography-guided Trucut needle biopsy (EUS-TNB) with EUS-guided fine-needle aspiration biopsy (EUS-FNAB) using 19- and 22-gauge needles for biopsy from different sites in patients with solid pancreatic cancers. PATIENTS AND METHODS: Sixteen consecutive patients with masses in the uncinate process (n = 3), the head (n = 5), or the body and tail (n = 8) of the pancreas underwent both EUS-TNB and EUS-FNAB. The specimens obtained were evaluated by histopathological analysis alone RESULTS: Tissue specimens were obtained by Trucut needle, and by 19-gauge and 22-gauge aspiration needles in 69 %, 69 %, and 100 % of patients respectively. Sensitivity for malignancy was 69 % for all needles. Tissue sampling by Trucut and by 19-gauge aspiration needle from masses in the uncinate process was impossible. The sensitivity of the Trucut and 19-gauge aspiration needles was 100 % in the 11 patients with successful procedures. If Trucut or 19-gauge aspiration needles had been used for body and tail masses, and the 22-gauge aspiration needle for masses in the uncinate process and head, the sensitivity for malignancy would have been 81 %. CONCLUSIONS: EUS-TNB allows reliable tissue sampling for the diagnosis of pancreatic masses, but its use is limited to lesions in the body and tail of the pancreas. EUS-FNAB using a 22-gauge needle may be useful for accurate diagnosis in some patients with masses in the uncinate process or the head of the pancreas.
